Dear Editor,
We have read the article by Sanz Diez et al. [1] ; however, we believe that some discussion is required. The authors have analyzed the axial length growth trend during the refractive development of Chinese schoolchildren.
In their analysis, high myopia was defined as a spherical equivalent refractive error (SER) of ≤ − 5.0 D. Using such a definition is controversial, as several organizations e.g., the American Academy of Ophthalmology, the American Optometric Association or the American Association for Pediatric Ophthalmology and Strabismus define high myopia as a SER of ≤ − 6.0 D [2, 3] . Using a cut-off value of − 5.0 D is not an error and is infrequently used, although the rationale for this approach is unclear. For example, Holden et al. state that they employed the cut-off value of ≤ − 5.0 D, as it was the most frequently used definition in studies included in their metaanalysis [4] . However, the online supplementary material clearly states that the cut-off value of ≤ − 6.0 D or < −6.0 D was used in 61.0% of the included publications. We believe that employing various definitions of refractive errors in future investigations can result in an even greater inconsistency in epidemiological studies. If we agree that an atypical threshold value of − 5.0 D can be applied, this might encourage other researchers to use different cut-off values when seeking for statistical significance in their results. Moreover, in such case, one might ask why should not we define high myopia as a SER greater than − 4.0 D or − 7.0 D.
It is obvious that even small changes of threshold definitions of refractive errors can affect frequency estimates in epidemiological studies. Applying various cut-off values can also create both false-positive and false-negative associations with risk factors [5] . Subsequently, these associations can significantly influence conclusions of epidemiological studies. Thus, we postulate employing the standardized definition of high myopia as a SER of − 6.0 D or greater in future studies.
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